Lupus Foundation of America

Phase 2b JASMINE trial of nipocalimab demonstrates positive results for treatment of systemic lupus erythematosus

Johnson & Johnson announced positive topline results from its Phase 2 randomized placebo-controlled JASMINE study. The drug ...
The Manila Times

Kailera Therapeutics Announces First Participants Randomized in KaiNETIC Global Phase 3 Clinical Program of GLP-1/GIP Receptor Dual Agonist Ribupatide (KAI-9531)

Ribupatide (KAI-9531) aims to address critical need for greater weight loss, especially for people living with a BMI of 35 kg ...
Medscape

Fremanezumab for Pediatric Migraine Prevention: Phase 3 SPACE Trial Results

Results of the SPACE trial demonstrating the safety and efficacy of subcutaneous fremanezumab for the prevention of pediatric ...
PsyPost on MSN

FDA-cleared brain stimulation device fails to beat placebo in ADHD trial

A large-scale clinical trial has determined that a specific brain stimulation device, previously cleared by regulators for ...
The New England Journal of Medicine

Baricitinib and β-Cell Function in Patients with New-Onset Type 1 Diabetes

Janus kinase (JAK) inhibitors, including baricitinib, block cytokine signaling and are effective disease-modifying treatments for several autoimmune diseases. Whether baricitinib preserves β-cell ...